Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P62070: Variant p.Gln72Leu

Ras-related protein R-Ras2
Gene: RRAS2
Feedback?
Variant information Variant position: help 72 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glutamine (Q) to Leucine (L) at position 72 (Q72L, p.Gln72Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (Q) to medium size and hydrophobic (L) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In NS12; also found as somatic mutation in ovarian cancer; increased MAPK signaling; results in craniofacial patterning defects when expressed in zebrafish. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 72 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 204 The length of the canonical sequence.
Location on the sequence: help TKQCVIDDRAARLDILDTAG Q EEFGAMREQYMRTGEGFLLV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         TKQCVIDDRAARLDILDTAGQEEFGAMREQYMRTGEGFLLV

Mouse                         TKQCVIDDRAARLDILDTAGQEEFGAMREQYMRTGEGFLLV

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 201 Ras-related protein R-Ras2
Binding site 68 – 72
Alternative sequence 1 – 77 Missing. In isoform 2.



Literature citations
A human oncogene of the RAS superfamily unmasked by expression cDNA cloning.
Chan A.M.-L.; Miki T.; Meyers K.A.; Aaronson S.A.;
Proc. Natl. Acad. Sci. U.S.A. 91:7558-7562(1994)
Cited for: SEQUENCE REVISION TO 5-11; TISSUE SPECIFICITY; VARIANT OVARIAN CANCER LEU-72; Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.
Capri Y.; Flex E.; Krumbach O.H.F.; Carpentieri G.; Cecchetti S.; Lissewski C.; Rezaei Adariani S.; Schanze D.; Brinkmann J.; Piard J.; Pantaleoni F.; Lepri F.R.; Goh E.S.; Chong K.; Stieglitz E.; Meyer J.; Kuechler A.; Bramswig N.C.; Sacharow S.; Strullu M.; Vial Y.; Vignal C.; Kensah G.; Cuturilo G.; Kazemein Jasemi N.S.; Dvorsky R.; Monaghan K.G.; Vincent L.M.; Cave H.; Verloes A.; Ahmadian M.R.; Tartaglia M.; Zenker M.;
Am. J. Hum. Genet. 104:1223-1232(2019)
Cited for: FUNCTION; SUBCELLULAR LOCATION; CATALYTIC ACTIVITY; INTERACTION WITH RASSF5; INVOLVEMENT IN NS12; VARIANTS NS12 VAL-23; GLY-GLY-GLY-24 INS; GLY-VAL-GLY-26 INS; THR-70 AND LEU-72; CHARACTERIZATION OF VARIANTS NS12 VAL-23; GLY-GLY-GLY-24 INS; GLY-VAL-GLY-26 INS; THR-70 AND LEU-72; Germline-Activating RRAS2 Mutations Cause Noonan Syndrome.
Niihori T.; Nagai K.; Fujita A.; Ohashi H.; Okamoto N.; Okada S.; Harada A.; Kihara H.; Arbogast T.; Funayama R.; Shirota M.; Nakayama K.; Abe T.; Inoue S.I.; Tsai I.C.; Matsumoto N.; Davis E.E.; Katsanis N.; Aoki Y.;
Am. J. Hum. Genet. 104:1233-1240(2019)
Cited for: FUNCTION; INVOLVEMENT IN NS12; VARIANTS NS12 GLY-VAL-GLY-26 INS; HIS-72; LEU-72 AND CYS-75; CHARACTERIZATION OF VARIANTS NS12 GLY-VAL-GLY-26 INS; HIS-72; LEU-72 AND CYS-75;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.